Table 2.
Case reports | Diagnosis | Clinical therapy & drug resistance | Reviews | Epidemiology | Immunology &molecular research and others | Total | |
P. carinii | 26 | 31 | 19 | 35 | 4 | 5 | 120 (30.9%) |
Cryptosporidium | 2 | 9 | 4 | 25 | 4 | 5 | 49 (12.6%) |
Toxoplasma | 8 | 2 | 3 | 18 | 6 | 9 | 46 (11.8%) |
Plasmodium | 1 | 1 | 6 | 9 | 2 | 4 | 23 (5.9%) |
Leishmania | 3 | 3 | 2 | 8 | 2 | 2 | 20 (5.2%) |
Amoeba | 2 | 0 | 0 | 2 | 0 | 1 | 5 (1.3%) |
Other | 14 | 4 | 7 | 90 | 7 | 3 | 125 (32.3%) |
Total | 56 (14.4%) | 50 (12.9%) | 41 (10.6%) | 187 (48.2%) | 25 (6.4%) | 29 (7.5%) | 388 (100%) |